HK/China Healthcare Analyst (ex-Fosun Pharma)

Xinyao (Criss) Wang

Over 15 years' experience in both finance and healthcare, covering clinic operations, investment and equity research in both China and overseas.

Goldlion Holdings (533 HK) Privatization - Updates on Valuation Outlook Based on 2024 Results

Pre-IPO Jiangsu Hengrui Medicine H Share Listing (PHIP Updates) - Some Points Worth the Attention

Pre-IPO Green Tea Group - Thoughts on IPO Pricing and Valuation Outlook

Tam Jai International (2217 HK) Privatization - The Offer Price Is Good

Shanghai Henlius Biotech (2696 HK)- LVC Is Betting on Higher Valuation Upside Due to Business Update

Pre-IPO Green Tea Group (PHIP Updates) - Some Points Worth the Attention

Equity Bottom-Up

<ul>
<li>The privatization failed due to the inability to balance the interests of public shareholders. There is a gap between the current Offer and the expectations of small and medium-sized investors.</li>
<li>Some shareholders may think Goldlion still has the potential for strategic adjustments/value reassessment, and are inclined to continue holding this stock. A cash reserve of HK$1.05 has given imagination space.</li>
<li>We are not sure what strategies Goldlion will adopt to address the current negative situation. The outlook is vague. 9-14x P/E could be reasonable valuation due to the short-term headwinds.</li>
</ul>


The privatization failed due to the inability to balance the interests of public shareholders. There is a gap between the current Offer and the expectations of small and medium-sized investors.
Some shareholders may think Goldlion still has the potential for strategic adjustments/value reassessment, and are inclined to continue holding this stock. A cash reserve of HK$1.05 has given imagination space.
We are not sure what strategies Goldlion will adopt to address the current negative situation. The outlook is vague. 9-14x P/E could be reasonable valuation due to the short-term headwinds.


Goldlion Holdings (533 HK) Privatization - About the Deal Break and the Valuation Outlook